financetom
Forex World Market Business Cryptocurrency Commodities MAP
financetom
Business
financetom
/
Business
/
Femasys Says FemBloc Non-Surgical Permanent Birth Control Gets European Approval; Shares Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Femasys Says FemBloc Non-Surgical Permanent Birth Control Gets European Approval; Shares Rise
Jun 25, 2025 7:59 AM

10:32 AM EDT, 06/25/2025 (MT Newswires) -- Femasys ( FEMY ) said Wednesday its FemBloc System for non-surgical female permanent birth control has received European regulatory approval.

The receipt of Conformite Europeene mark certification for the Class III FemBloc blended polymer component joins the earlier approval for FemBloc's delivery system component, the company said.

The company said the system can now be marketed in the European Economic Area, which includes the European Union's 27 member states and the three European Free Trade Association countries.

Femasys ( FEMY ) shares jumped 12% in recent trading.

Price: 0.99, Change: +0.11, Percent Change: +11.86

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sila Realty Trust's Q3 AFFO, Revenue Decline
Sila Realty Trust's Q3 AFFO, Revenue Decline
Nov 12, 2024
07:51 AM EST, 11/12/2024 (MT Newswires) -- Sila Realty Trust ( SILA ) reported Q3 adjusted funds from operations Tuesday of $0.57 per diluted share, compared with $0.60 a year earlier. Two analysts surveyed by Capital IQ expected $0.54. Revenue for the quarter ended Sept. 30 was $46.1 million, compared with $48.5 million a year earlier. One analyst surveyed by...
 Axsome Therapeutics Q3 Loss Widens, Revenue Increases
Axsome Therapeutics Q3 Loss Widens, Revenue Increases
Nov 12, 2024
07:52 AM EST, 11/12/2024 (MT Newswires) -- Axsome Therapeutics ( AXSM ) reported a Q3 loss Tuesday of $1.34 per share, widening from a loss of $1.32 a year earlier. Analysts polled by Capital IQ expected a loss of $1.41. Revenue for the quarter ended Sept. 30 was $104.8 million, up from $57.8 million a year earlier. Analysts surveyed by...
 Cronos Group Up 7.6% In US Premarket as Swings to Q3 Profit
Cronos Group Up 7.6% In US Premarket as Swings to Q3 Profit
Nov 12, 2024
07:55 AM EST, 11/12/2024 (MT Newswires) -- Cronos Group ( CRON ) , a global cannabinoid company, was at last look up 7.6% in US premarket trade on Tuesday after saying it swung to a profit in the third quarter on record net revenue and ongoing operating expense savings. The company, which also said it sees long-term margin improvement, reported...
 Sylvamo's Q3 Adjusted Operating Earnings, Net Sales Rise
Sylvamo's Q3 Adjusted Operating Earnings, Net Sales Rise
Nov 12, 2024
07:56 AM EST, 11/12/2024 (MT Newswires) -- Sylvamo ( SLVM ) reported Q3 adjusted operating earnings Tuesday of $2.44 per diluted share, up from $1.70 a year earlier. Three analysts polled by Capital IQ expected $2.18. Net sales for the quarter ended Sept. 30 were $965 million, up from $897 million a year earlier. Three analysts surveyed by Capital IQ...
About
Terms and Conditions Privacy policy Cookie Settings Contact Us
Services
Login register
financetom Market Personal Finance Business Economy Cryptocurrency MAP
Links
zpostcode Recruit weather mreligion Yellowpages sport constellation shopping name game directory literature Word tour furnish Lottery tftnews lyrics News digital car dir Edu Finance
Copyright 2023-2026 - www.financetom.com All Rights Reserved